Trials / Completed
CompletedNCT00408954
Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms
A Multi Center Randomized Cross Over Double Blind Third Party Open Placebo Controlled Pilot Study to Assess the Urodynamic Effects of Modified Release UK-369,003 in Men With Lower Urinary Tract Symptoms.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This is a pilot study to generate hypotheses about the urodynamic effects of UK-369,003 in men with lower urinary tract symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | UK-369,003 | 100 mg MR tablet once daily for 2 weeks |
| DRUG | UK-369,003 | UK-369,003-100 mg MR formulation for 2 weeks |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2006-12-08
- Last updated
- 2010-11-23
Locations
11 sites across 3 countries: Czechia, Netherlands, Slovakia
Source: ClinicalTrials.gov record NCT00408954. Inclusion in this directory is not an endorsement.